Topical oxybutynin antiperspirant for axillary hyperhidrosis: a phase IIb PROBE design clinical trial (TODAY trial)
Authors:
- Samantha NevesSNSamantha Neves
- Elisete Isabel CroccoECElisete Isabel Crocco
- Viviane Santana da SilvaVSViviane Santana da Silva
- Felipe MeneguetiFMFelipe Menegueti
- Alexia PaganottiAPAlexia Paganotti
- Ricardo Sanchez BoixRBRicardo Sanchez Boix
- Nelson WoloskerNWNelson Wolosker
- Roberto Augusto CaffaroRCRoberto Augusto Caffaro
Open Access
- 1 January 2026
- journal article
- Published by FapUNIFESP (SciELO) in Jornal Vascular Brasileiro
- Vol. 25, e20250065
Abstract
Background Primary hyperhidrosis is a chronic condition with limited therapeutic options. Objectives To evaluate the impact of 10% oxybutynin spray on axillary hyperhidrosis, considering both its local and systemic effects, in terms of Hyperhidrosis Disease Severity Scale (HDSS) outcomes for hyperhidrosis of the axilla and eight additional sites. Methods Prospective phase II PROBE design trial. Adult patients with axillary hyperhidrosis were randomized to receive a 10% oxybutynin topical spray, oral oxybutynin, or placebo spray for 35 days. Efficacy was evaluated on day 35 using the HDSS and a hyperhidrosis-specific quality-of-life (QoL) assessment questionnaire. Results 17 patients were randomized. No significant differences were observed in HDSS outcomes from baseline to day 35 in any of the three groups (2.5 [2 - 4], 4 [3 - 4], 3.5 [3 - 4], p= 0.207), although a trend to improvement was noted in both treatment groups. Significant improvement in the QoL questionnaire was observed from baseline to day 35 in the oxybutynin spray group (pre-intervention QoL: 78.5 [70 - 96] and post-intervention QoL: 38.5 [32 - 67], p = 0.031). Conclusions No differences were observed in the primary outcome. A significant improvement from baseline to day 35 was observed in the QoL questionnaire score for the oxybutynin spray group.Keywords
Funding Information
- Science Valley Research Institute
This publication has 26 references indexed in Scilit:
- A novel lotion formulation of 20% oxybutynin hydrochloride for the treatment of primary palmar hyperhidrosis: A randomized, placebo-controlled, double-blind, phase III studyJournal of the American Academy of Dermatology, 2023
- The Impact of Hyperhidrosis on Quality of Life: A Review of the LiteratureAmerican Journal of Clinical Dermatology, 2023
- Botulinum toxin: Pharmacology and injectable administration for the treatment of primary hyperhidrosisJournal of the American Academy of Dermatology, 2020
- The etiology, diagnosis, and management of hyperhidrosis: A comprehensive reviewJournal of the American Academy of Dermatology, 2019
- Topical Glycopyrronium Tosylate for the Treatment of Primary Axillary Hyperhidrosis: Patient-Reported Outcomes from the ATMOS-1 and ATMOS-2 Phase III Randomized Controlled TrialsAmerican Journal of Clinical Dermatology, 2018
- Pathophysiology of HyperhidrosisThoracic Surgery Clinics, 2016
- Botulinum Toxin for Axillary HyperhidrosisDermatologic Clinics, 2014
- Long-term Results of the Use of Oxybutynin for the Treatment of Axillary HyperhidrosisAnnals of Vascular Surgery, 2014
- The Use of Oxybutynin for Treating Axillary HyperhidrosisAnnals of Vascular Surgery, 2011
- Long-term Results and Quality-of-Life Measures in the Management of HyperhidrosisThoracic Surgery Clinics, 2008